Status:
COMPLETED
Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Polypoidal Choroidal Vasculopathy
Conbercept
Eligibility:
All Genders
50+ years
Brief Summary
1. To evaluate the effectiveness of Conbercept for PCV patients. 2. To describe the characteristics of PCV. 3. To describe the adverse events (AE) of Conbercept in the treatment of PCV. 4. Todescirbe ...
Detailed Description
1. To observe the visual changes in PCV patients receiving Conbercept treatment, so as to evaluate the effectiveness of the treatment. Changes of OCT, ICGA, quality of life and visual function would b...
Eligibility Criteria
Inclusion
- According to the current diagnostic criteria, diagnosed as PCV patients
- Conbercept is used for treatment, and the recommended treatment scheme is 3+PRN
- Local and systemic anti-VEGF therapy was not used for at least three months before enrollment
- The patient volunteers to take part in this observational study, and signs the informed consent
- The patient can follow-up regularly (at least 4 times of follow-up in one year)
Exclusion
- The patient has serious systemic disease, and the current clinical treatment is contraindicated
- Local or systemic anti-VEGF therapy was used for less than three months before enrollment
- Existence of diseases unsuitable to accept intravitreal Conbercept, including uncontrolled hypertension and diabetes, AIDS, malignant tumors, active hepatitis, severe renal failure, severe mental, nerve, cardiovascular, respiratory and immune diseases
- During six months before screening, there were cardiovascular events such as stroke, transient ischemic attack, myocardial infarction or acute congestive heart failure
- Ocular contraindications, including active intraocular inflammation, infectious endophthalmitis, corneal ulcer, scleritis, uncontrolled glaucoma and so on
- Patients who could not follow up regularly
- Patients who refuse to sign the informed consent
- Others
Key Trial Info
Start Date :
May 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 5 2021
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05229237
Start Date
May 1 2018
End Date
December 5 2021
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, China